EAN 2026 | The evolving treatment landscape for myasthenia gravis and emerging approaches on the horizon

Richard Nowak, MD, MS, Yale School of Medicine, New Haven, CT, discusses the evolving treatment landscape for myasthenia gravis. Dr Nowak highlights the recent approval of inebilizumab, as well as other strategies being explored, such as CAR T-cell therapy, telitacicept, and others. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.